Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- EndoRings Colonoscopy vs Standard Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of EndoRings Colonoscopy vs Standard Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03418662).
- Endoscopic Therapy of Early Cancer in Barretts Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Endoscopic Therapy of Early Cancer in Barretts Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00217087).
- EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: Complete Statistical AnalysisIndependent statistical analysis of EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ENESTopAn independent statistical analysis of the phase 2 ENESTop trial of nilotinib cessation after sustained MR4.5 in chronic myeloid leukemia, including its single-group design, treatment-free remission endpoint, planned statistical approach, reported safety…
- ENESTPathIndependent statistical analysis of A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.: primary endpoint results, effect estimate…
- Enhancing Community Capacity to Improve Cancer Care Delivery: Complete Statistical AnalysisIndependent statistical analysis of Enhancing Community Capacity to Improve Cancer Care Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04107116).
- Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ENVISIONIndependent statistical analysis of A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- ENZAMETIndependent statistical analysis of ENZAMET, a randomized phase 3 trial evaluating enzalutamide with androgen deprivation therapy for metastatic prostate cancer. Includes trial design, endpoints, planned analysis, and statistical interpretation.
- Enzastaurin for Patients With Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Enzastaurin for Patients With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00192114).
- Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ERECTIndependent statistical analysis of Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ERGO2Independent statistical analysis of Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00970502).
- Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05289830).
- ESOGIAIndependent statistical analysis of the ESOGIA phase 3 randomized trial evaluating classical versus optimized treatment allocation strategies for patients over 70 years of age with stage IV non-small-cell lung cancer.
- Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ESPAC-3An independent statistical analysis of ESPAC-3, a phase 3 randomized trial comparing chemotherapy regimens with observation in patients with completely resected pancreatic cancer.
- Estrogen for Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Estrogen for Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01083641).
- ETHOSA statistical and educational analysis of the ETHOS phase 3 randomized trial evaluating endoscopic full-thickness resection versus surgery for early colon cancer, including trial design, endpoints, planned analysis, and interpretation.
- Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Etirinotecan Pegol (NKTR-102) in NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Etirinotecan Pegol (NKTR-102) in NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01773109).
- Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer: Complete Statistical AnalysisIndependent statistical analysis of Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EURAMOS-1Complete statistical analysis of EURAMOS-1, a randomized phase 3 trial of combination chemotherapy, peginterferon alfa-2b, and surgery in patients with localized or metastatic osteosarcoma.
- EURTACIndependent statistical analysis of EURTAC, a randomized phase 3 trial comparing erlotinib with standard chemotherapy in advanced non-small cell lung cancer with EGFR TK-domain mutations, including progression-free survival, overall survival, trial design,…
- EVACELIndependent statistical analysis of Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01678664).
- Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation: Complete Statistical AnalysisIndependent statistical analysis of Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02348684).
- Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression: Complete Statistical AnalysisIndependent statistical analysis of Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Evaluating Cancer Survivorship Care Models: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Cancer Survivorship Care Models: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02362750).
- Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02982720).
- Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Evaluating Online Messages About Colon Cancer Screening: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Online Messages About Colon Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06134089).
- Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…